736
Views
2
CrossRef citations to date
0
Altmetric
Oncology

Health-related quality of life outcomes in chronic myeloid leukemia patients treated with second generation tyrosine kinase inhibitors: do we know enough?

&
Pages 1453-1454 | Received 25 Mar 2016, Accepted 27 Apr 2016, Published online: 12 May 2016

The introduction of tyrosine kinase inhibitors (TKIs) as frontline treatment for chronic myeloid leukemia (CML) has drastically changed the natural history of this disease. But since TKIs have to be continued lifelong, they have the potential to impact quality of life (QoL) in the long term. At baseline, it is now of paramount importance to consider, as potential criteria for selection, the social and psychological aspects of treatment in order to individualize a more patient-centered approach, one that will optimize treatment outcomes.

In the pivotal IRIS study, imatinib (i.e. the first targeted drug used in this population), was shown to improve health-related quality of life (HRQoL) compared to previous available therapies, such as interferon or chemotherapyCitation1. In the ILTE studyCitation2, patients were asked to report if imatinib administered in the long term interfered with HRQoL: 52% of patients answered that the drug influenced HRQoL because of the persistence of long-term mild adverse events. In the era of TKIs, the definition of intolerance to imatinib has changed considerably: not only is there the usual occurrences of adverse events that force a patient to discontinue the drug, but there are also persistent, low-grade adverse events that allow a patient to continue therapy that may adversely impact daily activities and HRQoLCitation3.

In a large study, that for the first time evaluated symptoms reported by patients in complete cytogenetic response (CCyR) with imatinib treated for a median time of 5 years, the symptom of fatigue was the most common side effect reported by 82% of patients. Also, one third of patients reported this symptom as moderate to severe despite the long time elapsed since diagnosis (median time of 5 years). Female patients were more prone to report side effects related to the drug, such as edema, fatigue and musculoskeletal pain. The sex effect was independent of age, education, duration of therapy, dose of imatinib and comorbiditiesCitation4.

However, little is known about the effects of the so-called “second generation” TKIs on patients’ HRQoLCitation5–13: the majority of studies were conducted using different patient-reported outcome measures and addressing different research questions. For example, a cross-sectional study involving 62 patients, of whom 19 were treated with nilotinib and 9 with dasatinib, showed that, compared to healthy controls, CML patients reported significantly worse fatigue, depression, symptom burden and physical impairmentCitation6. Another study enrolled 303 patients, 16% treated with nilotinib and 12.5% with dasatinib: patients treated with the first drug reported missing doses more often. Treatment satisfaction was associated with improved significant HRQoL and reduced activity impairment, whereas negative medication experiences were associated with decreased HRQoLCitation7.

For nilotinib as first line treatment, data stemming from the ENESTnd trial were recently presented in this journal. Adverse events were categorized into five broad categories (gastrointestinal, blood and lymphatic, general disorders, musculoskeletal, and psychiatric) and the incidence was lower for nilotinib compared to imatinib, but significantly impaired, even at low grade, QoL scoresCitation8. Kekale and colleagues reported the effects of adverse related events on medication adherence and perceived HRQoL in 86 patients treated with TKIs, of whom, 10.5% both with dasatinib and nilotinib, after a median time from diagnosis of 5.1 years. No relationships were found between adverse events and adherence, but there was a negative influence on daily HRQoL, in particular affecting mood, general conditions and enjoyment of lifeCitation9. More recently, in a prospective study including 53 patients treated first line with nilotinib, Lutge and colleaguesCitation10 showed that the HRQoL of CML patients increased over time with the exception of cognitive functioning. However, the differences were not statistically significant and the authors attributed this to possibly the small sample size.

HRQoL was also evaluated in the Spirit2 trial that tested dasatinib frontline vs. imatinib: several questionnaires were used including the EQ-5D and the FACT-BRM. Broadly, no HRQoL differences were found between the two arms; however, very few details were reported on the number of patients analyzed and the type of analysis performed making it difficult, at the present time, to understand the solidity of this dataCitation11.

HRQoL was also measured in patients treated with bosutinib after resistance (200 patients) or intolerance (88 patients) to imatinib. During treatment with bosutinib, the scale scores remained higher: at week 12 of treatment, significant improvement was observed in imatinib-resistant patients in physical well-being, emotional well-being, leukemia-specific subscale, FACT-leukemia total and FACT-TOI. In contrast, changes for imatinib-intolerant patients were not statistically significant at week 12, but started to be significant at week 24. At week 48, in both categories of patients, scores remained higher, suggesting improvement in HRQoLCitation12.

We read with interest the study reported by Whiteley et al. indicating HRQoL changes in advanced CML patients who were treated with bosutinib after imatinib failure. This study adds to the scarce data on the impact of newer TKIs on CML patients’ HRQoL. Even if the cohorts of patients were small, the study, first of its kind, indicated an improvement from baseline to week 24 in accelerated phase patients and from week 4 in blastic phase patientsCitation13.

Despite the availability of five TKIs, data reporting and HRQoL evaluation for all inhibitors tested in the first or second line are scarce. Most of the time, HRQoL was reported to be associated with randomized or sponsored clinical trials, therefore with highly selected entry criteriaCitation14. Moreover, several different tools were used in different trials and some of this evidence is also preliminary. Also, only a few studies assessed HRQoL in a “real-life” setting, examining and differentiating different subsets of CML patients, such as frontline treatment, second line, resistant or intolerant and advanced phase. With the availability of several drugs as front line and as a possible second line, we move towards a patient-centered approach: in this light, documenting HRQoL from a patient perspective is needed to evaluate overall treatment efficacy and tolerability. Therefore, there is need of additional research to better understand the impact of newer TKIs on the HRQoL of CML patients as it is expected that a growing number of patients will be treated with second or even third generation of TKIs in the near future. Patient reported outcomes (PROs) and evaluation of specific questionnaires created for CML patients (MDASI-CML and EORTC-CML24) should be suggested from baseline to clearly define the benefits of these drugs and to optimize treatment in case of impaired tolerance.

Transparency

Declaration of funding

This editorial was not funded.

Declaration of financial/other relationships

F.E. has disclosed that he is a consultant to Bristol-Myers Squibb and Seattle Genetics; and has received research funding from Bristol-Myers Squibb and Lundbeck. M.B. has disclosed that he has relevant financial relationships with Novartis and Bristol-Myers Squibb.

The CMRO peer reviewer on this manuscript has no relevant financial or other relationships to disclose.

References

  • Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS study. J Clin Oncol 2003;21:2138-46
  • Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011;103:553-61
  • Pinilla-Ibarz J, Cortes J. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer 2011;117:688-97
  • Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011;118:4554-60
  • Efficace F, Cardoni A, Cottone F, et al. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review. Leuk Res 2013;37:206-13
  • Phillips KM, Pinilla Ibarz J, Sotomayor E, et al. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 2013;21:1097-103
  • Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia: association of treatment satisfaction, negative medication experience and treatment restrictions with health outcome, from patient’s perspective. Health Qual Life Outcomes 2013;11:167
  • Guerin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin 2014;30:2317-28
  • Kekale M, Peltoniemi M, Airaksinen M. Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 2015;9:1733-40
  • Lutge I, Pfirrmann M, Stalljann I, et al. Health-related quality of life in CML patients under nilotinib first-line treatment: results of a German sub-study within the ENEST1st trial. Haematologica 2015;100(Suppl 1):abstract 233
  • Labeit AM, Copland M, Cork LM, et al. Assessment of quality of life in the NCRI Spirit 2 study comparing imatinib and dasatinib in patients with newly diagnosed chronic phase chronic myeloid leukemia. Blood 2015;126:abstract 4024
  • Trask PC, Cella D, Besson N, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012;36:438-42
  • Whiteley J, Reismann A, Shapiro M, et al. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin. 2016 May 5: 1-9. [Epub ahead of print]
  • Efficace F, Cocks K, Breccia M, et al. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes. Crit Rev Oncol Hematol 2012;81:123-35

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.